CJC-1295 & Ipamorelin

Why These Two Are Studied Together

UKPWritten & reviewed by William Heath · Editor, UK Peptides research library2 min readLast reviewed 2026-08-233 cited sources

The short answer

CJC-1295 acts at the GHRH receptor and ipamorelin at the ghrelin receptor, two distinct proteins converging on pituitary GH release. That non-overlap is a real mechanistic rationale for combination, though a rationale is not a demonstrated result.

Key facts

CJC-1295 receptor
GHRHR
Ipamorelin receptor
GHS-R1a
Convergence
Pituitary somatotrophs
Rationale
Independent stimulatory inputs
Usual pairing
Non-DAC form, matching half-lives
Evidence for additivity
Would require a factorial design

The rationale is unusually solid

Most combination arguments in this field assert mechanistic non-overlap without much behind it. Here it is true: GHRHR and GHS-R1a are separate G-protein-coupled receptors with separate endogenous ligands, and both are expressed on pituitary somatotrophs. Two independent inputs to one cell is a textbook setting for additive effects.

Why the non-DAC form is the usual partner

Matching kinetics. Ipamorelin is short-acting, and Modified GRF (1-29) clears in about thirty minutes, so the two produce overlapping brief stimuli. Pairing ipamorelin with the DAC form would combine a transient signal with a continuous one, which is a different experiment and arguably a less coherent one.

Research material referenced

CJC-1295 + Ipamorelin 5+5mg, third-party HPLC tested

Buy CJC-1295 + Ipamorelin · £42.99

What a rationale is not

It is not evidence of additivity. Establishing that requires a factorial design: each compound alone, both together, and neither, measured on the same endpoint in the same system. Without the single-agent arms there is no way to know whether a combined result exceeds what either produces by itself. REDEFINE 1 did exactly this for CagriSema against its components; no equivalent exists here.

The ceiling both share

Both are secretagogues, so both are limited by what the pituitary has and is willing to release. Somatostatin tone opposes both pathways. Combining two stimulatory inputs does not remove the inhibitory one, and the achievable output remains bounded by the gland rather than by the stimulus.

What is claimed here

Nothing about outcomes. The receptor pharmacology is well characterised and the combination rationale is coherent. Material supplied for laboratory research carries no claim about growth, recovery or body composition in any person.

Frequently asked questions

Why combine a GHRH analogue with a ghrelin receptor agonist?

They act at different receptors converging on the same pituitary cells, which is a real mechanistic rationale rather than an asserted one.

Has the combination been shown to be additive?

That would require a factorial design testing each alone and together. No such study establishes it.

Why the non-DAC form specifically?

Matching kinetics. Both are short-acting, producing overlapping brief stimuli rather than one transient and one continuous signal.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Browse the wider literature

Live database searches, not fixed citations. Results change as new work is indexed.

UKP

Written and reviewed by

William Heath · Editor, UK Peptides research library

William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.

More CJC-1295 & Ipamorelin articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.